Receptor-mediated radiotherapy with 90Y-DOTA-DPhe1-Tyr3-octreotide: The experience of the european institute of oncology group1
References (29)
- et al.
Somatostatin receptors and theirs subtypes in human tumors and in peritumoral vessels
Metabolism Clin Exp
(1996) - et al.
The in vivo release of 90Y from cyclic and acyclic ligand-antibody conjugates
Nucl Med Biol
(1991) - et al.
[111In-DTPA-D-Phe1] octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor — positive tumours: Synthesis, radiolabelling and in vitro validation
Life Sci
(1991) - et al.
Yttrium-90-labelled somatostatin-analogue for cancer treatment
Lancet
(1998) - et al.
Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro
Endocrinology
(1968) - et al.
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone
Science
(1973) - et al.
Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients
Eur J Nucl Med
(1993) Somatostatin-receptor imaging in the localization of endocrine tumors
N Engl J Med
(1990)- et al.
High density of somatostatin receptors in veins surrounding human cancer tissue: Role in tumor-host interactions?
Int J Cancer
(1994) - et al.
In situ radiotherapy with 111In-pentetreotide
Q J Nucl Med
(2000)
Receptor targeting for tumor localisation and therapy with radiopeptides
Curr Med Chem
(2000)
The peptide way to macrocyclic bifunctional chelating agents: Synthesis of 2-(p-nitroben-zyl)-1,4,7,10-tetraazacyclododecane-N,N′,N′',N′''-tetra-acetic acid and study of its Yttrium(III) complex
J Am Chem Soc
(1988)
Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent
J Nucl Med
(1990)
Radiometal-labelled macrocyclic chelator-derivatised somatostatin analogue with superb tumour-targeting properties and potential for receptor-mediated internal radiotherapy
Chem Eur J
(1999)
Cited by (125)
Peptide Receptor Radionuclide Therapy (PRRT) of Medullary and Nonmedullary Thyroid Cancer Using Radiolabeled Somatostatin Analogues
2016, Seminars in Nuclear MedicineAdvances in Peptide Receptor Radionuclide Therapy
2016, Seminars in Nuclear MedicineLong-term Nephrotoxicity after PRRT: Myth or Reality
2024, TheranosticsRecent advances in Targeted Radionuclide therapy for Cancer treatment
2023, Chemical Biology LettersPeptide Receptor Radionuclide Therapy in Thyroid Cancer
2022, Frontiers in Endocrinology
- 1
Supported by grants of the Italian association for Cancer Research (AIRC) and Consiglio Nazionale delle Ricerche (CNR-MIUR) PS Oncologia.
Copyright © 2002 Published by Elsevier Inc.